Search

Your search keyword '"Waage, Anders"' showing total 847 results

Search Constraints

Start Over You searched for: Author "Waage, Anders" Remove constraint Author: "Waage, Anders"
847 results on '"Waage, Anders"'

Search Results

1. Deciphering the genetics and mechanisms of predisposition to multiple myeloma

8. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

10. Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk

11. Functional dissection of inherited non-coding variation influencing multiple myeloma risk

12. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

13. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

14. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

15. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

17. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

18. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

19. Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk

20. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

21. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

25. Germline variants at SOHLH2 influence multiple myeloma risk

27. Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

28. P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

29. P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.

30. Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

31. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

32. Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma

33. Use of linked nordic registries for population studies in hematologic cancers : the case of multiple myeloma

34. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

35. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

39. Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines

40. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

41. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

43. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients

45. P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients

47. P-030: Regular monitoring with whole body low-dose CT for osteolysis in multiple myeloma reveals more cases of progressive bone disease than imaging performed by clinical indication

49. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

50. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group

Catalog

Books, media, physical & digital resources